Jim Cramer: Will Valeant Rebound?
Valeant may be reeling, but the embattled drug company has a number of things going for it, says TheStreet's Jim Cramer.
Valeant (VRX) may be reeling, but the embattled drug company has a number of things going for it including the support of hedge fund manager Bill Ackman and the potential sale of its Bausch & Lomb business, said TheStreet's Jim Cramer. Nevertheless, despite all those potentially positive factors, Cramer advises caution on the name because of its debt load and sales outlook.
At the time of publication, Jim Cramer's charitable trust Action Alerts PLUS held no positions in stocks mentioned.
